Nuclear Medicine and Biology
Volume 37, Issue 3 , Pages 265-275 , April 2010

In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours — impact of peptide mass

  • Irina Velikyan

      Affiliations

    • Department of Biochemistry and Organic Chemistry, BMC, Uppsala University, Box 599, SE-751 24 Uppsala, Sweden
    • Uppsala Applied Science Lab, GEMS PET Systems, GE Healthcare, SE-752 28 Uppsala, Sweden
    • ,
  • Anders Sundin

      Affiliations

    • Department of Radiology, Karolinska University Hospital, SE-171 76 Stockholm, Sweden
    • ,
  • Barbro Eriksson

      Affiliations

    • Department of Endocrine Oncology, Uppsala University Hospital, SE-751 85 Uppsala, Sweden
    • ,
  • Hans Lundqvist

      Affiliations

    • Department of Oncology, Radiology and Clinical Immunology, Uppsala University, SE-751 85 Uppsala, Sweden
    • ,
  • Jens Sörensen

      Affiliations

    • Department of Medicinal Sciences, Clinical Physiology and Nuclear Medicine, Uppsala University Hospital, SE-751 85 Uppsala, Sweden
    • ,
  • Mats Bergström

      Affiliations

    • Department of Pharmaceutical Biosciences, Uppsala Biomedical Centre, Uppsala University, Uppsala, Sweden
    • ,
  • Bengt Långström

      Affiliations

    • Department of Biochemistry and Organic Chemistry, BMC, Uppsala University, Box 599, SE-751 24 Uppsala, Sweden
    • Corresponding Author InformationCorresponding author. PET Centre, Department of Biochemistry and Organic Chemistry, Uppsala University, Box 967, SE-751 09 Uppsala, Sweden. Tel.: +46 18 666900; fax: +46 18 666819.

Received 2 October 2009 ,Revised 28 October 2009 ,Accepted 25 November 2009.

References 

  1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–959
  2. Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol. 2001;12:1295–1300
  3. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–731
  4. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15:966–973
  5. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med Mol Imaging. 2000;27:273–282
  6. Wild D, Macke HR, Waser B, Reubi JC, Ginj M, Rasch H, et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005;32:724
  7. Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. (68)Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2008;35:72–79
  8. Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med. 2009;50:936–941
  9. de Herder WW, Kwekkeboom DJ, Valkema R, Feelders RA, van Aken MO, Lamberts SW, et al. Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Invest. 2005;28:132–136
  10. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717–1751
  11. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med. 2002;43:610–616
  12. Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab. 2007;21:111–129
  13. Pauwels P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom AT, Sciot R. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology. 2005;47:41–47
  14. Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, et al. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003;30:510–518
  15. Helisch A, Forster GJ, Reber H, Buchholz HG, Arnold R, Goke B, et al. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1386–1392
  16. Win Z, Al-Nahhas A, Towey D, Todd JF, Rubello D, Lewington V, et al. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun. 2007;28:359–363
  17. Win Z, Rahman L, Murrell J, Todd J, Al-Nahhas A. The possible role of 68Ga-DOTATATE PET in malignant abdominal paraganglioma. Eur J Nucl Med Mol Imaging. 2006;33:506
  18. Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med. 2005;46:763–769
  19. Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A, et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys. 2006;65:222–227
  20. Wei L, Miao Y, Gallazzi F, Quinn TP, Welch MJ, Vavere AL, et al. Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma. Nucl Med Biol. 2007;34:945–953
  21. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508–518
  22. Hofmann M, Weitzel T, Krause T. Ga-68-DOTATOC: Feasibility of high throughput screening by small animal PET using a clinical high-resolution PET/CT scanner. Nucl Instrum Methods Physics Res Sec A: Accelerators, Spectrometers, Detectors Assoc Equipment. 2006;569:522–524
  23. Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003;5:42–48
  24. Velikyan I, Beyer GJ, Langstrom B. Microwave-supported preparation of 68Ga-bioconjugates with high specific radioactivity. Bioconjug Chem. 2004;15:554–560
  25. Velikyan I., Långström B. Microwave method for preparing radiolabelled gallium complexes. WO 2004/089425, 2004.
  26. Velikyan I., Långström B., and Beyer G. Method of obtaining gallium-68 and use thereof and device for carrying out said method. WO 2004/089517, 2004.
  27. Bernhardt P, Kolby L, Johanson V, Nilsson O, Ahlman H, Forssell-Aronsson E. Biodistribution of 111in-DTPA-D-Phe1-octreotide in tumor-bearing nude mice: influence of amount injected and route of administration. Nucl Med Biol. 2003;30:253–260
  28. de Jong M, Breeman WA, Bernard BF, van Gameren A, de Bruin E, Bakker WH, et al. Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount. Eur J Nucl Med. 1999;26:693–698
  29. Velikyan I, Beyer GJ, Bergstrom-Pettermann E, Johansen P, Bergstrom M, Langstrom B. The importance of high specific radioactivity in the performance of (68)Ga-labeled peptide. Nucl Med Biol. 2008;35:529–536
  30. Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer. 2008;112:2447–2455
  31. Wahl RL. Tositumomab and (131)I therapy in non-Hodgkin's lymphoma. J Nucl Med. 2005;46(Suppl 1):128S–140S

PII: S0969-8051(09)00288-1

doi: 10.1016/j.nucmedbio.2009.11.008

Nuclear Medicine and Biology
Volume 37, Issue 3 , Pages 265-275 , April 2010

Article Tools

* Image Usage & Resolution